RxDoctor Payments Data

Danielle Johnson

Family · Cheraw, SCNPI 1447602057

Payments from drug & device makers

$1,417in general payments, 2019–2025

Across 74 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$460
  • Novo Nordisk$157
  • Boehringer Ingelheim$118
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$101
  • Lilly USA, LLC$94
  • GSK$81
  • plus $407 from 13 others

What the payments were for

  • Food & beverage$1,417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,417 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$11,406
Medicare patients
107
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$59,537
OzempicSemaglutide56$51,251
JardianceEmpagliflozin41$45,716
FarxigaDapagliflozin Propanediol51$43,899
EliquisApixaban43$28,892
TrulicityDulaglutide14$22,315
Tresiba Flextouch U-100Insulin Degludec13$10,447
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,525
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,108
Albuterol Sulfate HfaAlbuterol Sulfate57$2,151
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic19$1,394
Gabapentin124$1,230
Duloxetine Hcl71$1,030
Atorvastatin Calcium119$986
Nifedipine ErNifedipine65$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$94$81,85370 claims
Novo NordiskOzempic$157$51,25156 claims
Boehringer IngelheimJardiance$118$45,71641 claims
AstraZenecaFarxiga$25$43,89951 claims
GSKTrelegy Ellipta$81$8,52511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Cheraw

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →